Our Journey

2018

CD70CAR T-Cell Study
in Glioblastoma (GBM)
Published in Neuro-
Oncology

-
8R-70CAR
Patent Filed

2019

8R-70CAR T-Cell Study
Published in Nature
Communications

2021

IND (#23881) Approved
for Phase I Trials

2023

aLAIR1 Antibody
Patent Filed
-
8R-70CAR Patent Granted

2024

Immunogenik Founded

2025

NIH STTRs Funded for IND-Enabling Studies
-
aLAIR1 Study Published in J. Clincial Investigation
-
Exlusive Option Agreements with UF (8R70CAR, aLAIR1)

* Immunogenik holds an exclusive option agreement with the University of Florida for licensing of the technologies

About Us

Our Mission
At Immunogenik, our mission is to develop and translate innovative cancer immunotherapy approaches to help cancer patients. We are an interdisciplinary team of scientists, clinicians, and entrepreneurs who are working together to develop and apply new technologies for understanding and treating cancer. We strive to bring together the best minds in the field of cancer immunotherapy to develop better treatments and improve the lives of cancer patients.

Governance & Compliance
Immunogenik is committed to operating with the highest standards of governance, compliance, and risk management. We are proactively building the infrastructure, from corporate governance to regulatory readiness and insurance protections, to responsibly advance our science and clinical development programs.

Our Team

Board Members